Palvella Therapeutics (PVLA) 12th Annual Cantor Fitzgerald Global Healthcare Conference summary

Strategic vision and platform overview

• Focus on rare skin diseases and vascular anomalies with no FDA-approved therapies, aiming to be the first to market in each indication.

• QTORIN platform enables reproducible generation of novel topical therapies, with a multi-layered exclusivity strategy including patents, trade secrets, and regulatory protections.

• Lead product, QTORIN rapamycin, targets microcystic lymphatic malformations (microLM), with NDA filed and anticipated FDA approval in the first half of 2027.

• Platform's anhydrous formulation is optimized for high dermal drug delivery and minimal systemic exposure, with molecule-specific development for each program.

• Small changes in formulation or manufacturing significantly impact product performance, creating high barriers to generic entry.

Intellectual property and competitive barriers

• Six issued patents and over 150 claims on QTORIN rapamycin, with protection extending to at least 2038 and pending patents potentially into the mid-2040s.

• Trade secrets in manufacturing and formulation further protect against generic replication.

• Orphan drug designation provides seven years of exclusivity for microLM, blocking generics unless they show clear incremental advantage.

• FDA considers QTORIN a complex product, requiring generics to meet higher technical thresholds for bioequivalence, including in vitro release and skin penetration studies.

• Aqueous formulations are less viable due to solubility and stability issues with rapamycin.

Clinical development and regulatory progress

• NDA for QTORIN rapamycin in microLM submitted, with Priority Review requested and multiple expedited FDA designations granted.

• Phase III SELVA trial showed 95% patient improvement and 86% much or very much improved.

• Market research indicates strong physician preference for the FDA-approved product over compounded alternatives.

• Pricing guidance is $100,000–$200,000 per patient per year, with payer testing showing favorable coverage even above $200,000.

• Commercial strategy targets high-volume centers and leverages field checks and claims analysis to estimate a diagnosed U.S. patient pool of over 30,000 for microLM.